anticholesteremic agents

Summary

Summary: Substances used to lower plasma cholesterol levels.

Top Publications

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
  2. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
  3. ncbi Effects of torcetrapib in patients at high risk for coronary events
    Philip J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    N Engl J Med 357:2109-22. 2007
  4. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
  5. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
  6. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
  7. ncbi Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
    Weijia Kong
    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China
    Nat Med 10:1344-51. 2004
  8. ncbi Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
    Scott W Altmann
    Department of Cardiovascular Endocrine Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ, 07033 0539, USA
    Science 303:1201-4. 2004
  9. ncbi Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    Frederick J Raal
    Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
    Lancet 375:998-1006. 2010
  10. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007

Research Grants

  1. MEMBRANE COMPOSITION AND HYPERTHERMIC CELL DEATH
    MILTON YATVIN; Fiscal Year: 1990
  2. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
  3. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
  4. Pharmacogenetics of the Statin Response
    ERNST SCHAEFER; Fiscal Year: 2006
  5. DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
    ERNST SCHAEFER; Fiscal Year: 2003
  6. MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
    ERNST SCHAEFER; Fiscal Year: 2009
  7. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
  8. Long-Term Exercise Maintenance via Internet Support
    Paul Williams; Fiscal Year: 2006
  9. Gene-Specific Responses to Exercise in Discordant Twins
    Paul Williams; Fiscal Year: 2007
  10. PROSPECTIVE STUDY OF HEALTH IN RUNNERS AND WALKERS
    Paul Williams; Fiscal Year: 2002

Detail Information

Publications350 found, 100 shown here

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  2. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  3. ncbi Effects of torcetrapib in patients at high risk for coronary events
    Philip J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    N Engl J Med 357:2109-22. 2007
    ..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib...
  4. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
    ..Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke...
  5. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  6. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
    ..Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear...
  7. ncbi Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
    Weijia Kong
    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China
    Nat Med 10:1344-51. 2004
    ..These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs...
  8. ncbi Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
    Scott W Altmann
    Department of Cardiovascular Endocrine Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ, 07033 0539, USA
    Science 303:1201-4. 2004
    ..Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout mice, suggesting that NPC1L1 resides in an ezetimibe-sensitive pathway responsible for intestinal cholesterol absorption...
  9. ncbi Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    Frederick J Raal
    Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
    Lancet 375:998-1006. 2010
    ..This study investigated whether an antisense inhibitor of apolipoprotein B synthesis, mipomersen, is effective and safe as an adjunctive agent to lower LDL cholesterol concentrations in patients with this disease...
  10. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007
    ..9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial...
  11. ncbi A systematic review and meta-analysis on the therapeutic equivalence of statins
    T C Weng
    Institute of Clinical Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    J Clin Pharm Ther 35:139-51. 2010
    ..As the number of patients in need of statin therapy continues to increase, information regarding the relative efficacy and safety of statins is required for decision-making...
  12. ncbi Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment
    Frederick J Raal
    Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    Atherosclerosis 223:262-8. 2012
    ..The purpose of this review is to provide current perspectives on diagnosis and therapy in an effort to encourage early recognition and treatment of this rare but severe disease...
  13. ncbi Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
    ..We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol...
  14. ncbi Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
    Haruo Nakamura
    Mitsukoshi Health and Welfare Foundation, Tokyo, Japan
    Lancet 368:1155-63. 2006
    ..Our aim was to assess whether evidence for treatment with statins derived from western populations can be extrapolated to the Japanese population...
  15. ncbi Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
    Rory Collins
    Lancet 363:757-67. 2004
    ..Despite this observation, previous randomised trials had indicated that cholesterol-lowering statin therapy reduces the risk of stroke, but large-scale prospective confirmation has been needed...
  16. ncbi Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels
    Martijn B Katan
    Division of Human Nutrition and Epidemiology, Wageningen University, Bomenweg 2, 6703 HD Wageningen, The Netherlands
    Mayo Clin Proc 78:965-78. 2003
    ..However, present evidence is sufficient to promote use of sterols and stanols for lowering LDL cholesterol levels in persons at increased risk for coronary heart disease...
  17. ncbi Effect of torcetrapib on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:1304-16. 2007
    ..Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, increases HDL cholesterol levels, but the functional effects associated with this mechanism remain uncertain...
  18. ncbi Statin-associated myopathy
    Paul D Thompson
    Preventive Cardiology and Cardiovascular Research, Division of Cardiology, Hartford Hospital, Hartford, Conn 06102, USA
    JAMA 289:1681-90. 2003
    ..How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance...
  19. ncbi Where are we with probucol: a new life for an old drug?
    Shizuya Yamashita
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    Atherosclerosis 207:16-23. 2009
    ..Therefore, probucol could be a more common therapeutic drug for the treatment of patients with FH as well. There is more than enough reason to believe that this old drug has much more to offer than hitherto known...
  20. ncbi The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
    T A Pearson
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
    Arch Intern Med 160:459-67. 2000
    ....
  21. ncbi Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial
    Kaspar Berneis
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Eur Heart J 31:1633-9. 2010
    ..This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution...
  22. ncbi Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, 3288 Illinois Ave, Louisville, KY 40213, USA
    Arch Intern Med 168:1975-83. 2008
    ..Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM)...
  23. ncbi Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arch Intern Med 168:1531-40. 2008
    ..Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus. Achieving glycemic control safely with insulin therapy can be challenging...
  24. ncbi C-reactive protein levels and outcomes after statin therapy
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:20-8. 2005
    ..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown...
  25. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
    ..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease...
  26. ncbi A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients
    William L Baker
    University of Connecticut School of Pharmacy, Storrs, CT, USA
    Ann Nutr Metab 55:368-74. 2009
    ..To better characterize the impact of chitosan on serum lipids in hypercholesterolemic patients, we performed a meta-analysis of randomized controlled trials...
  27. ncbi Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis
    Dimitri P Mikhailidis
    Department of Clinical Biochemistry Vascular Disease Prevention Clinics, University College London UCL Medical School, London, UK
    Curr Med Res Opin 27:1191-210. 2011
    ..To systematically review and analyse evidence for cholesterol-lowering efficacy of at least 4 weeks of add-on ezetimibe vs doubling statin dose, in adults with primary hypercholesterolaemia...
  28. ncbi Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells
    Junichi Fukuchi
    The Ben May Institute for Cancer Research and The Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 64:7686-9. 2004
    ..Based on these results, modulation of the liver X receptor signaling pathway is a new target for controlling tumor cell proliferation; therefore, liver X receptor agonists may have utility as antitumorigenic agents...
  29. ncbi Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes
    M Fiegenbaum
    Departamento de Genetica, Instituto de Biociencias, Universidade Federal do Rio Grande do Sul, 91501 970 Porto Alegre, RS, Brazil
    Pharmacogenomics J 5:359-64. 2005
    ..8%), whereas only 29% of 2386A homozygous reached this reduction (P=0.009). Our data suggest that the SCAP 2386A>G gene polymorphism was a significant predictor of TC and triglyceride responses to simvastatin treatment...
  30. ncbi Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients
    Yoh Miyashita
    Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, 564 1 Shimoshizu, Chiba, Japan
    J Atheroscler Thromb 17:1070-6. 2010
    ..High cholesterol absorption in the small intestine has been proposed to be a risk factor of atherosclerosis. In this study, we evaluated the effect of ezetimibe monotherapy on arterial stiffness in type 2 diabetic patients...
  31. ncbi Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice
    Maho Sumiyoshi
    Division of Functional Histology, Department of Integrated Basic Medical Science, School of Medicine, Ehime University, Shitsukawa, Toon City, Ehime 791 0295, Japan
    J Pharm Pharmacol 58:201-7. 2006
    ..It was concluded that water-soluble 46-kDa chitosan is a safe functional food...
  32. ncbi Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
    Holly E Careskey
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 49:394-8. 2008
    ..These results suggest that the addition of a PCSK9 inhibitor to statin therapy may result in even further LDL-C decreases...
  33. ncbi Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
    Fatima Akdim
    Department of Vascular Medicine, Academic Medical Center Amsterdam, Meibergdreef 9, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
    Eur Heart J 32:2650-9. 2011
    ..A randomized, double-blind, placebo-controlled, dose-escalation study was designed to evaluate the efficacy and safety of mipomersen monotherapy with or without dose loading in subjects with mild-to-moderate hyperlipidaemia...
  34. ncbi Chronic treatment with the peroxisome proliferator-activated receptor alpha agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function
    Makhosazane Zungu
    Hatter Heart Research Institute, Department of Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa
    Mol Cell Biochem 330:55-62. 2009
    ..This study demonstrates that chronic in vivo Wy-14,643 administration impaired cardiac contractile function in parallel with decreased mitochondrial respiratory function and increased uncoupling...
  35. ncbi Is raising HDL a futile strategy for atheroprotection?
    Tisha Joy
    Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A 5K8
    Nat Rev Drug Discov 7:143-55. 2008
    ..In this article, we review the complexity of HDL metabolism, discuss clinical-trial data for HDL-raising agents, including possible reasons for the failure of torcetrapib, and consider the potential for future HDL-based therapies...
  36. pmc Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet
    Dick C Chan
    Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Diabetes Care 33:1134-9. 2010
    ..Weight loss and/or pharmacotherapy are commonly used to correct these abnormalities...
  37. pmc Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
    Maartje E Visser
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Eur Heart J 33:1142-9. 2012
    ....
  38. ncbi Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
    M H Davidson
    Radiant Research, Chicago, IL 60610 4324, USA
    Int J Clin Pract 58:746-55. 2004
    ..Ezetimibe + statin had a safety profile similar to statin monotherapy. Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia...
  39. pmc Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study
    Robert S Rosenson
    University of Michigan, Ann Arbor, Michigan, USA
    Diabetes Care 32:1087-91. 2009
    ..Changes in lipoprotein particle concentration may predict the risk of coronary heart disease more accurately than lipoprotein cholesterol levels...
  40. ncbi Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: bridging Niemann-Pick disease type C and Alzheimer's disease
    Chor Hui Vivien Koh
    Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore
    Cell Signal 18:1844-53. 2006
    ....
  41. ncbi Cholesterol movement in Niemann-Pick type C cells and in cells treated with amphiphiles
    Y Lange
    Department of Pathology, Rush Presbyterian St Luke s Medical Center University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 275:17468-75. 2000
    ....
  42. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  43. ncbi Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    A M Gotto
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Circulation 101:477-84. 2000
    ..This article describes the relation between baseline and on-treatment lipid and apolipoprotein (apo) parameters and subsequent risk for AMCEs...
  44. ncbi Structural mechanism for statin inhibition of HMG-CoA reductase
    E S Istvan
    Department of Biochemistry, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center at Dallas, TX 75390 9050, USA
    Science 292:1160-4. 2001
    ..Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding...
  45. ncbi A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors
    F Malekzadeh
    Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Int J Clin Pract 64:1220-7. 2010
    ..Our objective was to investigate the effects and tolerability of fixed-dose combination therapy on blood pressure and LDL in adults without elevated blood pressure or lipid levels...
  46. ncbi Genetic analysis of digestive physiology using fluorescent phospholipid reporters
    S A Farber
    Department of Embryology, Carnegie Institution of Washington, Baltimore, MD 21210, USA
    Science 292:1385-8. 2001
    ..Thus, fluorescent lipids provide a sensitive readout of lipid metabolism and are a powerful tool for identifying genes that mediate vertebrate digestive physiology...
  47. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008
    ..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic rabbits...
  48. ncbi Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 204:208-15. 2009
    ..To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia...
  49. ncbi Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy
    Thomas A Pearson
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Am J Cardiol 103:369-74. 2009
    ..The effects of ezetimibe monotherapy are not well defined. The effects of ezetimibe on CRP were consistent across patient subgroups...
  50. pmc Extracellular loop C of NPC1L1 is important for binding to ezetimibe
    Adam B Weinglass
    Departments of Ion Channels, Medicinal Chemistry, and Pharmacology, Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065, USA
    Proc Natl Acad Sci U S A 105:11140-5. 2008
    ..Specifically, EZE binding to an extracellular site distinct from where cholesterol binds prevents conformational changes in NPC1L1 that are necessary for the translocation of cholesterol across the membrane...
  51. ncbi Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 344:1959-65. 2001
    ..We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia...
  52. ncbi Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
    J Musial
    Department of Medicine, Jagiellonian University School of Medicine, Skawinska 8, 31 066, Krakow, Poland
    Int J Cardiol 77:247-53. 2001
    ..The aim of the study was to assess the influence of simvastatin and aspirin on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in hypercholesterolemic subjects...
  53. ncbi Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein
    David J A Jenkins
    Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
    JAMA 290:502-10. 2003
    ....
  54. ncbi Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans
    Lena Persson
    Department of Endocrinology, Center for Biosciences and Nutrition, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Arterioscler Thromb Vasc Biol 30:2666-72. 2010
    ..To gain insight into the function of proprotein convertase subtilisin kexin type 9 (PCSK9) in humans by establishing whether circulating levels are influenced by diurnal, dietary, and hormonal changes...
  55. ncbi Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet
    Tomonori Muraoka
    Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama 236 0004, Japan
    Metabolism 60:617-28. 2011
    ..Ezetimibe down-regulated SREBP-1c in the liver and reversed hepatic insulin resistance in mice fed a high-fat diet...
  56. ncbi Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects
    T D T Nguyen
    Department of Microbiology, Pukyong National University, Busan 608 737, Republic of Korea
    Int J Food Microbiol 113:358-61. 2007
    ..05) in body weight, visceral weigh index or bacteria translocation between two groups were observed. The results indicated that L. plantarum PH04 might be effective as a probiotic with cholesterol-lowering activities...
  57. ncbi Safety of anacetrapib in patients with or at high risk for coronary heart disease
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 363:2406-15. 2010
    ..Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol...
  58. ncbi Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Peter S Sever
    Imperial College, London, UK
    Lancet 361:1149-58. 2003
    ..No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic...
  59. ncbi The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1
    Liang Ge
    State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Cell Metab 7:508-19. 2008
    ..Together, our data suggest a model wherein cholesterol is internalized into cells with NPC1L1 through clathrin/AP2-mediated endocytosis and ezetimibe inhibits cholesterol absorption by blocking the internalization of NPC1L1...
  60. ncbi The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 51:1632-41. 2008
    ..This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk...
  61. pmc Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine
    Hai Li
    Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Biol Chem 284:28885-95. 2009
    ..This is the first described example of SREBP pairing with HNF1 to control an important regulatory pathway in cholesterol homeostasis. This work also provides a mechanism for how BBR suppresses PCSK9 transcription...
  62. ncbi Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
    C P Sparrow
    Merck Research Laboratories, Rahway, NJ, USA
    Arterioscler Thromb Vasc Biol 21:115-21. 2001
    ..These data support the hypothesis that simvastatin has antiatherosclerotic activity beyond its plasma cholesterol-lowering activity...
  63. ncbi Berberine decreases PCSK9 expression in HepG2 cells
    Jamie Cameron
    Medical Genetics Laboratory, Department of Medical Genetics, Rikshospitalet University Hospital, Oslo, Norway
    Atherosclerosis 201:266-73. 2008
    ..Mutations in the PCSK9 gene have been shown to cause either hypo- or hypercholesterolemia. Here we investigated the effect of berberine, a natural plant extract, on PCSK9 expression in HepG2 cells...
  64. pmc Statin therapy inhibits remyelination in the central nervous system
    Veronique E Miron
    Neuroimmunology Unit, the Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Am J Pathol 174:1880-90. 2009
    ....
  65. ncbi Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials
    J C LaRosa
    Office of the President, State University of New York Health Science Center at Brooklyn, 11203, USA
    JAMA 282:2340-6. 1999
    ..Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women...
  66. ncbi Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
    Vincent J Willey
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Curr Med Res Opin 26:121-8. 2010
    ..The current study examines simvastatin therapy modification patterns and associated low-density lipoprotein cholesterol (LDL-C) goal attainment rates...
  67. ncbi Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 291:1071-80. 2004
    ..Statin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality. However, the optimal strategy and target level for lipid reduction remain uncertain...
  68. ncbi Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels
    Steven A Grover
    McGill Cardiovascular Health Improvement Program and Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada
    Arch Intern Med 169:1775-80. 2009
    ..We examined data from the Framingham Offspring Study from 1975 through 2003 to determine whether increases in HDL-C levels after lipid therapy was started were independently associated with a reduction in CV events...
  69. pmc Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis
    Ishwarlal Jialal
    Laboratory for Atherosclerosis and Metabolic Research, University of California, Davis Medical Center, Sacramento, California 95817, USA
    Metab Syndr Relat Disord 7:255-8. 2009
    ..In conclusion, COL represents a novel therapeutic option by significantly lowering both LDL-C and HbA1c in patients with T2DM, two important treatment goals to forestall vascular complications...
  70. ncbi Lipid-lowering response to statins is affected by CYP3A5 polymorphism
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:523-5. 2004
    ..These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins...
  71. pmc Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial
    Thuy Anh Le
    Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Hepatology 56:922-32. 2012
    ..MRI-PDFF correlated strongly with MRS-determined hepatic fat content (r(2) = 0.96, P < 0.0001). Liver biopsy assessment of steatosis, cellular injury, and lobular inflammation did not detect any effect of treatment...
  72. ncbi Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance
    Tetsuji Tsunoda
    Division of Metabolism and Endocrinology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, Yokohama, Japan
    Diabetes Res Clin Pract 100:46-52. 2013
    ..To evaluate the effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance...
  73. ncbi Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
    Daniel I Chasman
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215, USA
    Circ Cardiovasc Genet 5:257-64. 2012
    ..However, interindividual variation in low-density lipoprotein cholesterol (LDL-C) response to statins is wide and may partially be determined on a genetic basis...
  74. ncbi Very high plant stanol intake and serum plant stanols and non-cholesterol sterols
    Helena Gylling
    Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland
    Eur J Nutr 49:111-7. 2010
    ..Today, consumers meet abundant supply of functional foods with plant stanol increments for serum cholesterol lowering purposes. However, efficacy and safety of plant stanols intake beyond 4 g/day have remained unexplored...
  75. ncbi Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus
    Karl Winkler
    Department of Clinical Chemistry, University Medical Center Freiburg, Hugstetter Straße 55, D 79106 Freiburg, Germany
    Atherosclerosis 220:189-93. 2012
    ..We thus determined the concentration of atherogenic small, dense LDL (sdLDL) in patients with type 2 diabetes and an elevated cardiovascular risk profile...
  76. ncbi Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis
    M C Ramirez-Tortosa
    Department of Biochemistry and Molecular Biology, University of Granada, Faculty of Pharmacy, Campus de Cartuja 18071, Granada, Spain
    Atherosclerosis 147:371-8. 1999
    ..2-mg dosage. In conclusion, the use of this extract could be useful in the management of cardiovascular disease in which atherosclerosis is important...
  77. ncbi Endothelial function in hypercholesterolemic subjects: Effects of plant stanol and sterol esters
    Maarit Hallikainen
    Department of Clinical Nutrition, University of Kuopio, P O Box 1627, 70211 Kuopio, Finland
    Atherosclerosis 188:425-32. 2006
    ..2% (p=0.012) from STAEST. In conclusion, variables of cholesterol metabolism are associated with brachial artery diameter at baseline. STEEST diminishes brachial artery diameter, but its clinical relevance remains unclear...
  78. ncbi Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans
    Wahida Karmally
    The Irving Center for Clinical Research, Columbia University Medical Center, New York, NY 10032, USA
    J Am Diet Assoc 105:967-70. 2005
    ..2+/-18.3 mg/dL; 1.1%) or LDL-C (+1.2+/-17.5 mg/dL; 2.2%). Differences between the effects of the two cereals on total cholesterol and LDL-C were significant, P =.0003 and P =.0007, respectively...
  79. pmc CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia
    F Raal
    Department of Medicine, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
    Cardiovasc J Afr 22:234-40. 2011
    ....
  80. ncbi Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients
    Kaan Tunceli
    Global Health Outcomes, Merck, Whitehouse Station, NJ 08889 0100, USA
    J Clin Lipidol 4:491-500. 2010
    ..The availability of generic simvastatin in 2006 has prompted substantial changes in formulary recommendations for lipid-management agents...
  81. ncbi Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease
    Yusuke Uemura
    Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo, Japan
    J Cardiol 59:50-6. 2012
    ..Changes in serum lipids, including malondialdehyde-modified LDL (MDA-LDL) as a representative form of oxidized LDL cholesterol, and glucose metabolism were assessed...
  82. pmc Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Cardiovasc Drugs Ther 25:47-57. 2011
    ....
  83. pmc Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
    Thomas F Luscher
    Department of Cardiology, Cardiovascular Centre, University of Zurich, 8091 Zurich, Switzerland
    Eur Heart J 33:857-65. 2012
    ..gov number NCT00655538)...
  84. ncbi Ezetimibe and vascular inflammation
    Toshiyuki Ishibashi
    Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960 1295, Japan
    Curr Vasc Pharmacol 9:99-108. 2011
    ..This review provides information on recently described clinical trials of ezetimibe monotherapy, stain monotherapy, and combined therapy for LDL-C lowering and vascular inflammation...
  85. ncbi The pathology of atherosclerosis: plaque development and plaque responses to medical treatment
    William Insull
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, and Lipid Research Clinic, Baylor College of Medicine, Houston, Texas 77030 3411, USA
    Am J Med 122:S3-S14. 2009
    ..Thus, atherosclerosis, a disease heretofore viewed as inevitably progressive, can be treated to significantly alter arterial lesions and reduce their clinical consequences...
  86. ncbi Human cholesterol metabolism and therapeutic molecules
    V Charlton-Menys
    Cardiovascular Research Group, School of Clinical and Laboratory Sciences, Core Technology Facility 3rd floor, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK
    Exp Physiol 93:27-42. 2008
    ....
  87. ncbi Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?
    Olivier S Descamps
    Department of Internal Medicine, Hopital de Jolimont, Haine Saint Paul, Belgium
    Atherosclerosis 217:308-21. 2011
    ..At present, the use of the plasma levels of plant sterols and cholesterol precursors as markers of cholesterol absorption and synthesis is far too limited to definitively solve these questions...
  88. ncbi Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study
    Talieh Kazerooni
    Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran
    Fertil Steril 94:2208-13. 2010
    ..To evaluate the effect of a combination of simvastatin and metformin on biochemical parameters in women with polycystic ovary syndrome (PCOS)...
  89. ncbi Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
    Eli M Roth
    Sterling Research Group, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:175-86. 2010
    ....
  90. ncbi Anacetrapib: hope for CETP inhibitors?
    Ronen Gurfinkel
    Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A 5K8
    Cardiovasc Ther 29:327-39. 2011
    ..This article will briefly review the HDL-C raising through CETP inhibition as an antiatherogenic strategy with a specific focus on anacetrapib...
  91. ncbi Does statin therapy influence steroid hormone synthesis?
    M Bohm
    Klinik fur Innere Medizin III, Universitatskliniken des Saarlandes, Kirrberger Strasse, 66421 Homburg, Germany
    Z Kardiol 93:43-8. 2004
    ..There was no compensatory change in FSH or LH. It is concluded that pravastatin does not alter steroid hormones or gonadotropins in a clinically applicable dose, which significantly reduces total and LDL cholesterol...
  92. ncbi Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
    Jennifer G Robinson
    University of Iowa College of Public Health, Iowa City, Iowa, USA
    Am J Cardiol 103:1694-702. 2009
    ..In conclusion, ezetimibe/simvastatin was more likely to result in lipid treatment end points than atorvastatin and was generally well tolerated at the doses compared in our patients...
  93. ncbi Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial
    G G Schwartz
    Cardiology Section 111B, Denver VA Medical Center, 1055 Clermont St, Denver, CO 80220, USA
    JAMA 285:1711-8. 2001
    ....
  94. ncbi The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study
    Alejandra Meaney
    Cardiovascular Unit, Regional Hospital, 1 de Octubre, ISSSTE, Mexico
    J Clin Pharmacol 49:838-47. 2009
    ..This study is one of the first providing evidence that dual therapy has a beneficial effect on a surrogate marker of atherosclerosis...
  95. pmc Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport
    Eric J Smart
    Department of Physiology, University of Kentucky, Lexington, KY 40536, USA
    Proc Natl Acad Sci U S A 101:3450-5. 2004
    ..Pharmacological treatment of mice with ezetimibe disrupts the heterocomplex in only hypercholesterolemic animals. These data suggest that ANX2 and CAV1 are components of an intestinal sterol transport complex...
  96. ncbi Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
    F Affuso
    Department of Internal Medicine, Cardiovascular and Immunologic Sciences, University of Naples Federico II, Naples, Italy
    Nutr Metab Cardiovasc Dis 20:656-61. 2010
    ..We evaluated the effects of a nutraceutical combination (NC), consisting of 500 mg berberine, 200mg red yeast rice and 10mg policosanols, on cholesterol levels and endothelial function in patients with hypercholesterolemia...
  97. ncbi Statins and other cholesterol-lowering medications and the presence of glaucoma
    Gerald McGwin
    Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Birmingham, USA
    Arch Ophthalmol 122:822-6. 2004
    ..To explore whether oral statin and other antihyperlipidemic medications are associated with open-angle glaucoma...
  98. ncbi Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study
    Louise A Donnelly
    Division of Community Health Sciences, Mackenzie Building, Kirsty Semple Way, Dundee, Scotland, UK
    Pharmacogenet Genomics 18:279-87. 2008
    ..We sought to evaluate the association of the APOE genotype with the low-density lipoprotein cholesterol (LDLc)-lowering response to statins, in a large population-based cohort of patients with diabetes...
  99. pmc Ezetimibe therapy: mechanism of action and clinical update
    Binh An P Phan
    Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA
    Vasc Health Risk Manag 8:415-27. 2012
    ....
  100. ncbi Do statins affect androgen levels in men? Results from the Boston area community health survey
    Susan A Hall
    New England Research Institutes, 9 Galen Street, Watertown, MA 02472, USA
    Cancer Epidemiol Biomarkers Prev 16:1587-94. 2007
    ....
  101. ncbi Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    Curr Opin Lipidol 22:288-95. 2011
    ....

Research Grants72

  1. MEMBRANE COMPOSITION AND HYPERTHERMIC CELL DEATH
    MILTON YATVIN; Fiscal Year: 1990
    ..These studies of adaptive thermotolerance and hyperthermic lethality are intended to answer questions relevant to the design of clinical studies using hyperthermia...
  2. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  3. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  4. Pharmacogenetics of the Statin Response
    ERNST SCHAEFER; Fiscal Year: 2006
    ..These results can be used to formulate guidelines for identifying elderly subjects for statin treatment to prevent future CHD. ..
  5. DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
    ERNST SCHAEFER; Fiscal Year: 2003
    ..abstract_text> ..
  6. MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
    ERNST SCHAEFER; Fiscal Year: 2009
    ..The results of this work will provide important insight into the contribution of allelic variation in the pathways of HDL metabolism, inflammation, and insulin resistance to the complex phenotype of low HDL-C. ..
  7. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
    ....
  8. Long-Term Exercise Maintenance via Internet Support
    Paul Williams; Fiscal Year: 2006
    ..We estimate that we will be able to detect differences in exercise cessation rates between the intervention and control group of 0.45% in runners and walkers separately (alpha=0.05, 80% statistical power). ..
  9. Gene-Specific Responses to Exercise in Discordant Twins
    Paul Williams; Fiscal Year: 2007
    ..DNA samples will be shared with other institutions to cross-validate gene associations identified from training studies or other designs. ..
  10. PROSPECTIVE STUDY OF HEALTH IN RUNNERS AND WALKERS
    Paul Williams; Fiscal Year: 2002
    ..1%). Additionally, a detectable reduction in breast cancer risk as small as 1.5% per mile run in women is calculated, which is below the 1.7% reduction in risk estimated from other published data. ..
  11. Radiology Cancer Research Training Curriculum
    Thomas Pearson; Fiscal Year: 2005
    ..The curriculum will be seamlessly integrated within the confines of a radiology residency or fellowship program. ..
  12. LINKING RESOURCES FOR BROWN MEDICAL NUTRITION EDUCATION
    Charles Eaton; Fiscal Year: 2002
    ....
  13. Translating ATP III Cholesterol Management Guidelines *
    Charles Eaton; Fiscal Year: 2006
    ..abstract_text> ..
  14. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  15. UNIVERSITY OF ROCHESTER NUTRITION ACADEMIC AWARD PROGRAM
    Thomas Pearson; Fiscal Year: 2002
    ..Dissemination of the curriculum and educational tools will be facilitated by programs in professional societies, collaboration with the food industry, and development of an easily accessible Website. ..
  16. CLINICAL RESEARCH CURRICULUM
    Thomas Pearson; Fiscal Year: 2004
    ..With completion of the RCRC, the trainee should have the theoretical, methodological, and practical knowledge and skills for a productive career in clinical research. ..
  17. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  18. PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDS
    Virgil Brown; Fiscal Year: 2004
    ..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
  19. CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION
    Scott Grundy; Fiscal Year: 2002
    ..The long term goal is to produce graduates who routinely address nutrition and exercise for cardiovascular health with their patients. ..
  20. CARDIAC VALVE CALCIFICATION
    Emile Mohler; Fiscal Year: 2003
    ..2. To investigate mechanisms of valve calcification using a cell culture model of calcification. 3. To examine therapeutic strategies to inhibit valve calcification with a bisphosphonate in cell culture. ..
  21. ABCs of Intestinal Sterol Transport
    F Field; Fiscal Year: 2009
    ..The results of this proposal will provide new and novel information on the roles of the ABC transporters, NPC1L1, and lipid rafts in intestinal sterol metabolism ..
  22. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2009
    ..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
  23. Heavy Drinking & Coronary Disease: Acute/Chronic Effects
    Kenneth Mukamal; Fiscal Year: 2006
    ..These results may prove to have important biological, clinical, and public health implications for the care of CHD. ..
  24. Coenzyme Q10 in Aging: A Planning Grant
    Beatrice Golomb; Fiscal Year: 2005
    ..Thus there is strong conceptual as well as clinical rationale for assessing whether Q10 provides QOL & functional benefits in aging and whether it protects against untoward events associated with age. ..
  25. Role of Insulin Regulation of Beta Cell Function in Vivo and in Vitro
    Allison Goldfine; Fiscal Year: 2008
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  26. NUTRITION ACADEMIC AWARD
    Robert Knopp; Fiscal Year: 2002
    ..It is time to begin aggressive, substantive nutrition educational programs in cardiovascular disease prevention. ..
  27. Nanoparticles for Molecular MRI of Atherosclerosis
    Zahi Fayad; Fiscal Year: 2008
    ..These studies will provide the basis for future advances in experimental studies of atherosclerogenesis and new clinical applications of non-invasive, in vivo MR imaging of atherosclerotic lesions. [unreadable] [unreadable] [unreadable]..
  28. STATINS AND NON-CARDIAC ENDPOINTS
    Beatrice Golomb; Fiscal Year: 2003
    ....
  29. PHYSIOLOGY AND MOLECULAR DETERMINANTS OF DIABETES
    Allison Goldfine; Fiscal Year: 2004
    ....
  30. Sitosterolemia
    Gerald Salen; Fiscal Year: 2003
    ..Sitosterolemia is a rare disease but understanding the mechanism of enhanced sterol absorption and accumulation will provide key information to formulate better treatment of atherosclerosis in the general population. ..
  31. Endothelial Dysfunction, Oxidative Stress and Risk of Peripheral Arterial Disease
    Kenneth Jay Mukamal; Fiscal Year: 2010
    ..Finally, we will examine how a derived dietary antioxidant score, based upon measured oxidative potential of specific foods using the ferric-reducing/antioxidant power method, is related to PAD. ..
  32. Adherence & Health Outcomes after Liver Transplantation
    Carol S Stilley; Fiscal Year: 2010
    ..The application of this research would serve as the basis to advance significantly the nation's capacity to protect and preserve health in transplant populations. ..
  33. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  34. KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
    Frank Sacks; Fiscal Year: 2001
    ..These studies will increase our understanding of the metabolic pathways that are activated or suppressed postprandially, and could lead to treatments for reducing the development of atherosclerosis. ..
  35. Mechanistic study of CHD risk in subjects with high HDLC
    Marina Cuchel; Fiscal Year: 2008
    ....
  36. MUTATION ANALYSIS OF THYROID HORMONE FUNCTION
    John Baxter; Fiscal Year: 2009
    ..These studies should provide substantial insight into TR function that is relevant for understanding TR action, mechanism of action of other NRs, regulation of gene expression and pharmaceutical design. ..
  37. CRP, Diabetes, Atherothrombosis
    Ishwarlal Jialal; Fiscal Year: 2010
    ..CRP augments oxidative stress and inflammation in the diabetic milieu will eventually lead to therapies targeted at reducing inflammation and oxidative stress in diabetes and resulting in a decrease in vasculopathies ..
  38. Vein wall remodeling after DVT is matrix metalloproteinase dependent
    Peter Henke; Fiscal Year: 2009
    ..This proposal will provide important mechanistic insight into the pathophysiology of post-phelbitic syndrome with real potential translation to decreasing the morbidity from this under-acknowledged disease. ..
  39. Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
    Lori J Mosca; Fiscal Year: 2010
    ..Improved adherence to evidence-based preventive therapies could have a substantial public health benefit. ..
  40. Electronic Diary Assessment of Pain in Juvenile Arthritis
    Laura E Schanberg; Fiscal Year: 2010
    ..Finally, the study can serve as a catalyst for future research aimed at advancing medical and psychological knowledge of pain in other pediatric medical populations. ..
  41. EXTRACELLULAR SUPEROXIDE DISMUTASE AND ATHEROSCLEROSIS
    David Harrison; Fiscal Year: 2001
    ....
  42. Redox Signaling in Osteoblast Differentiation
    Nandini Ghosh Choudhury; Fiscal Year: 2009
    ..Understanding the signal transduction pathways of osteoblast differentiation may result in the development of therapeutic modalities for the human diseases where lack of bone formation is the pathology. ..
  43. CELL SURFACE METABOLISM OF MACROPHAGE DERIVED APO E
    Theodore Mazzone; Fiscal Year: 2001
    ..In this Specific Aim we will more thoroughly examine the metabolism of LDL and ALDL as it is influenced by the cell surface pool of macrophage derived apo E. ..
  44. Effect of Antioxidants on Inflammatory Markers and FMVD
    Christopher Gardner; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  45. Apo A2, C1 and C2 and Diet in human apoB Metabolism
    Frank Sacks; Fiscal Year: 2005
    ..abstract_text> ..
  46. Do Statins Ameliorate Periodontal Disease?
    Barry Saver; Fiscal Year: 2005
    ....
  47. Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
    Robert Henry; Fiscal Year: 2004
    ..abstract_text> ..
  48. High Dose Alpha Tocopherol and Carotid Atherosclerosis
    Ishwarlal Jialal; Fiscal Year: 2004
    ..This study has the additional novelty of correlating biomarkers of oxidative stress and inflammation with a cardiovascular endpoint and will establish whether high dose AT decreases atherosclerosis progression. ..
  49. Reducing Risk Factors in Peripheral Arterial Disease
    Mary Mcgrae McDermott; Fiscal Year: 2010
    ....
  50. Conference--Wound Healing : O2 and Emerging Therapeutics
    Chandan Sen; Fiscal Year: 2002
    ..Oxygen Sensing Oxidant Signaling & Redox Regulated Gene Expression Oxygen Therapy of Wounds Potential and Limitations of Clinical Gene Therapy for Wound Care Wound Angiogenesis Inflammation and Bacterial Control Clinical Care ..
  51. Effects of Statins on AD beyond Cholesterol and Amyloid
    Ling Li; Fiscal Year: 2006
    ..abstract_text> ..
  52. VLDL and LDL Particle Types as CHD Risk Factors
    Frank Sacks; Fiscal Year: 2006
    ..abstract_text> ..
  53. Human Subjects Research Enhancements Program
    Frederick Samaha; Fiscal Year: 2003
    ..The sharing of electronic systems will allow Tri-Health to upgrade their research compliance program. ..
  54. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
    ..However the treatment duration will be increased to a total of 10 sessions. ..
  55. Personality and Medication Adherence in Transplantation
    CAROL STILLEY; Fiscal Year: 2003
    ..medication regimes. The goal of the, a relatively new researcher, is to gain experience in order to develop more extensive study of psychological factors which better explain and predict treatment adherence after organ transplantation. ..
  56. Genetic Epidemiology of Blood Pressure Intervention
    Jiang He; Fiscal Year: 2008
    ..In addition, identifying genes related to salt-sensitivity and potassium-sensitivity of BP should enable the discovery of new pharmaceutical treatment for hypertension. [unreadable] [unreadable] [unreadable]..
  57. NEW PATHWAY LIMITS CELLULAR CHOLESTEROL CONTENT
    Phoebe Fielding; Fiscal Year: 2004
    ..Each of these studies has significant relevance to the basis of FC accumulation in atherosclerosis. ..
  58. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
    ..abstract_text> ..
  59. Inflammatory response to sleep apnea in obese subjects
    JULIO ALONSO CHIRINOS MEDINA; Fiscal Year: 2010
    ..We propose that this study design will provide the best way to separate the independent effects of obesity and OSA on cardiovascular risk. ..
  60. CAROTID PLAQUE COMPOSITION BY MRI DURING LIPID-LOWERING
    Xue Qiao Zhao; Fiscal Year: 2010
    ....
  61. Inflammatory Mechanisms of Atherosclerosis
    Peter Libby; Fiscal Year: 2006
    ..5. We will explore a putative functional role of a novel prostaglandin E2 receptor EP4 interacting protein (EPRAP) in endogenous anti-inflammatory pathways. ..
  62. Kern Aspen Lipid Conference
    Alan Tall; Fiscal Year: 2007
    ..End of Abstract) [unreadable] [unreadable] [unreadable]..
  63. ETHANOL METABOLISM IN PREGNANCY--ROLE OF DIET
    Martin Ronis; Fiscal Year: 2005
    ....
  64. Regulation of stearoyl-CoA desaturases by oleate
    Douglas Thewke; Fiscal Year: 2004
    ..Ectotopic expression of SREBPs or other trans-acting factors will be used to determine their contribution to oleate regulation of SCD transcription. ..
  65. Lens Cholesterol Metobolism and the U1866A Cataract.
    RICHARD CENEDELLA; Fiscal Year: 2005
    ..These are obvious benefits to public health considering the intended life-long use of the drugs. ..
  66. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  67. LENS MEMBRANE STEROID BINDING PROTEIN (MSRP)
    RICHARD CENEDELLA; Fiscal Year: 2002
    ..Preliminary findings and published data support the possibility that steroids can rapidly elevate intracellular calcium and inhibit Na+/K+-ATPase activity in lens epithelial cells. ..
  68. Role of ABCG5 and ABCG8 in Sterol Metabolism
    Helen Hobbs; Fiscal Year: 2007
    ..These studies will provide a comprehensive understanding of the molecular mechanisms of this important transport system that protects against hypercholesterolemia and coronary atherosclerosis. ..